GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...

Patients with eosinophilic granulomatosis with polyangiitis experienced significant improvements in a variety of outcomes ...

A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy ...

The U.S. Food and Drug Administration extended the review of KalVista Pharmaceuticals' drug for a type of hereditary swelling ...

This FTSE 100 pharmaceutical giant has been hit by fears of US tariffs and litigation over a key product, but this could mean ...

According to an internal email, the agency may be in for more consolidation in areas including human resources, ...

The Food and Drug Administration has gone all in on AI since Martin Makary, M.D., took over the agency, most recently ...

At close: 3:30:02 PM GMT+5:30 ...